A
Arjun Narayanan
Researcher at Pfizer
Publications - 15
Citations - 706
Arjun Narayanan is an academic researcher from Pfizer. The author has contributed to research in topics: DCPS & Catalysis. The author has an hindex of 8, co-authored 15 publications receiving 491 citations. Previous affiliations of Arjun Narayanan include University of Southern California.
Papers
More filters
Journal ArticleDOI
Sulfonyl fluorides as privileged warheads in chemical biology
Arjun Narayanan,Lyn H. Jones +1 more
TL;DR: The use of sulfonyl fluoride probes in chemical biology is reviewed and three new probes are introduced that provide new insights into the mechanism behind the formation of fluoride in seawater.
Journal ArticleDOI
Rational Targeting of Active-Site Tyrosine Residues Using Sulfonyl Fluoride Probes
Erik C. Hett,Hua Xu,Kieran F. Geoghegan,Ariamala Gopalsamy,Robert E. Kyne,Carol A. Menard,Arjun Narayanan,Mihir D. Parikh,Shenping Liu,Lee R. Roberts,Ralph P. Robinson,Michael A. Tones,Lyn H. Jones +12 more
TL;DR: This work describes the first rational targeting of tyrosine residues in a protein binding site by small-molecule covalent probes, illustrating the utility of sulfonyl fluoride probes designed to react with specific tyrosines of a protein and augments the chemical biology toolkit by these probes uses in target validation and molecular pharmacology.
Journal ArticleDOI
Fluorine in drug design: a case study with fluoroanisoles.
Li Xing,David C. Blakemore,Arjun Narayanan,Ray Unwalla,Frank Lovering,R. Aldrin Denny,Huanyu Zhou,Mark E. Bunnage +7 more
TL;DR: Whereas replacing PhOCH3 with PhOCF3 is a common tactic to optimize ADME properties, the analysis suggests Ph OCF2H may be a more attractive alternative, and greater exploitation of this motif is recommended.
Journal ArticleDOI
Understanding and applying tyrosine biochemical diversity
TL;DR: This review highlights some of the recent advances made in understanding of the diversity of tyrosine biochemistry and shows how this has inspired novel applications in numerous areas of molecular design and synthesis, including chemical biology and bioconjugation.
Journal ArticleDOI
PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease.
Ariamala Gopalsamy,Ann Aulabaugh,Amey Barakat,Kevin Beaumont,Shawn Cabral,Daniel P. Canterbury,Agustin Casimiro-Garcia,Jeanne S. Chang,Ming Z. Chen,Chulho Choi,Robert L. Dow,Olugbeminiyi O. Fadeyi,Xidong Feng,Roger M. Howard,Jay M. Janz,Jayasankar Jasti,Reema Jasuja,Lyn H. Jones,Amanda King-Ahmad,Kelly M. Knee,Jeffrey T. Kohrt,Chris Limberakis,Spiros Liras,Carlos A. Martinez,Kim F. McClure,Arjun Narayanan,Jatin Narula,Jonathan J. Novak,Thomas N. O'Connell,Mihir D. Parikh,David W. Piotrowski,Olga Plotnikova,Ralph P. Robinson,Parag Sahasrabudhe,Raman Sharma,Benjamin A. Thuma,Dipy Vasa,Liuqing Wei,A. Zane Wenzel,Jane M. Withka,Jun Xiao,Hatice G. Yayla +41 more
TL;DR: In this paper, a non-covalent modulator of HbS, PF-07059013 (23), has been developed and tested on mice with Townes SCD.